IMIoannis V. Mitselos

Ioannis V. Mitselos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ioannis V. Mitselos has a total of 39 co-authors. Here are the top co-authors by number of shared publications:

  • Dimitrios K. Christodoulou

    Department of Gastroenterology, University Hospital of Ioannina, 45500 Ioannina, Greece

    6 shared publications
  • Athina Tatsioni

    Internal Medicine, School of Health Sciences, Faculty of Medicine, University Hospital of Ioannina, University of Ioannina, Ioannina, Greece

    2 shared publications
  • Epameinondas V Tsianos

    Department of Gastroenterology, School of Health Sciences, University Hospital of Ioannina, Faculty of Medicine, University of Ioannina, Ioannina, Greece

    2 shared publications
  • Konstantinos H. Katsanos

    Departments of Gastroenterology

    2 shared publications
  • Rami Eliakim

    Department of Gastroenterology, Sheba Medical Center & Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel

    2 shared publications
  • Aleksandra Rapti

    Gastroenterology

    1 shared publication

Latest Publications

  • Open Access

    Body mass index for the assessment of adiposity in healthy aging Caucasian women: a dual-energy X-ray absorptiometry based study

    by Stavroula J. Theodorou, Daphne J. Theodorou, Ioannis Mitselos, Vassiliki Kigka, Andreas Fotopoulos, Andreas F. Mavrogenis

    Accurate classification of obesity levels is of clinical importance for public health and decision making. Body mass index (BMI) is the most broadly used measure of obesity on a population scale. But, as with other diagnostic indicators, BMI can have potential pitfalls. We attempted to explore the diagnostic performance of BMI for assessing obesity. 330 healthy Caucasian women (native Greeks) (ages, 20 to 85 years) volunteers participated in the study. Dual-energy X-ray absorptiometry (DXA) was used to measure percentage of fat mass (%FM). The diagnostic performance of BMI was assessed using the widely used indicator for obesity of %FM > 35% in women. Receiver operating characteristic (ROC) analysis was performed to evaluate the ability of BMI to discriminate obesity from non obesity. The correlation between BMI and %FM, and lean mass (LM) and %LM, was also investigated. Logistic regression was performed to assess for associations between DXA-derived fat metrics and age. BMI-defined obesity (≥ 30 kg/m 2 ) was present in 40.3% of women, while %FM DXA-defined obesity was present in 72% of the subjects. The largest discrepancy between BMI- and DXA-defined obesity was noted in women over 80 years (p = 0.0002). A BMI ≥ 30 kg/m 2 had excellent sensitivity [99%, 95% confidence interval (CI), 95.8–99.9], but poor specificity [45%, 95% CI 38–52] to detect %FM-based obesity. BMI ≥ 25 kg/m 2 had high sensitivity (92%, 95% CI 87.5–94.8) and good specificity (79%, 95% CI 68.7–86.6). The optimal cut point for BMI in the entire cohort found to correspond closer to the criterion value of 35%FM was 26.32 kg/m 2 (p < 0.001). At this level, BMI had excellent sensitivity (96.7%, 95% CI 93.3–98.6) and moderate specificity (71.5%, 95% CI 62.4–79.5). In all women, BMI correlated better with %FM (r = 0.74 to 0.84, p < 0.05) than with %LM (r= −0.68 to −0.86, p < 0.05). Logistic regression analysis found age was a significant predictor of obesity (OR = 1.074, 95% CI 1.036–1.114, p < 0.05), increasing odds for excess adiposity by 7.4% each year. The diagnostic performance of BMI for assessing obesity is limited particularly in women with BMI ≥ 30 kg/m 2 . A BMI cut point ≥ 30 kg/m 2 has very high sensitivity, but misclassifies as obese 55% of normal women. At the BMI cut off ≥ 25 kg/m 2 sensitivity was high, but 21% of women were still misclassified as obese. A BMI cut point value of 26.32 kg/m 2 has higher sensitivity and falsely classifies as obese 28% of the women. In light of these findings, revision of current BMI criteria for obesity screening may be warranted in white women of Mediterranean origin such as Greek women, and perhaps other populations.


  • Open Access

    Randomized Trial of Midazolam Plus Meperidine Versus Midazolam Plus Fentanyl Versus Placebo for Colonoscopic Sedation

    by Miltiadis K. Moutzoukis, Ioannis V. Mitselos, Nikoletta Karavasili, Vasileios Theopistos, Alexandros Skamnelos, Dimitrios Sigounas, Varvara Pantazi, Panagiota Moschou, Dimitrios K. Christodoulou

    Objective: A combination of midazolam and opioid is usually used to achieve conscious sedation and analgesia during colonoscopy, but many patients may tolerate the procedure well without any sedation. This randomized trial aimed to compare the efficacy and recovery time of 3 different regimens consisting of (a) midazolam plus meperidine (b) midazolam plus fentanyl and (c) placebo. The endoscopists’ and patients’ satisfaction was assessed by an appropriate questionnaire. Methods: A total 248 consecutive, unselected patients attending outpatient colonoscopy at a University Hospital were enrolled with informed consent and were randomized to receive (a) midazolam with meperidine [group A] (b) midazolam with fentanyl [group B] or (c) placebo [group C]. Data for procedure times, perceived patient’s discomfort (using a relative patient questionnaire) and physician’s satisfaction from the procedure were collected. Patients and all endoscopy staff directly involved with the procedure except the research nurse were blinded to the regimens used. Results: The mean age of the patients was 58 ± 15 years (range 19–85 years) and 130 were males. The completion rate and time to reach cecum did not differ among the three groups. The recovery time was significantly shorter in group C (placebo, 10.4 ± 2.9 min) compared to the other groups (p < 0.000), but it was also shorter in group B (midazolam plus fentanyl, 43.0 ± 9.3 min) compared to group A (midazolam plus pethidine, 50.1 ± 9.0 min) (p = 0.001). Patients of group B (midazolam plus fentanyl) experienced less pain and discomfort than patients of group A (midazolam plus meperidine) (p = 0.02) and patients of group A experienced less pain than patients of group C (placebo). Many more patients in group B were extremely or very satisfied by the procedure(86.7%) compared to group A (59.7%) and group C (44.5%) (p = 0.001). Adverse events were mild in all groups and slightly less in group B. Conclusions: Sedation with midazolam and fentanyl was more effective, better tolerated and led to slightly faster recovery time than sedation with midazolam and meperidine. According to our findings and the literature, the most appropriate regimen for conscious sedation during colonoscopy is the combination of midazolam and fentanyl. However, both sedation regimens were proven to be effective and safe and even a significant proportion of unsedated patients could tolerate the procedure fairly well.

  • Open Access

    Medical, Endoscopic and Surgical Management of Stricturing Crohn’s Disease: Current Clinical Practice

    by Fotios S. Fousekis, Ioannis V. Mitselos, Kostas Tepelenis, George Pappas-Gogos, Konstantinos H. Katsanos, Georgios D. Lianos, Francesco Frattini, Konstantinos Vlachos, Dimitrios K. Christodoulou

    The development of fibrostenotic intestinal disease occurs in approximately one-third of patients with Crohn’s disease and is associated with increased morbidity. Despite introducing new biologic agents, stricturing Crohn’s disease remains a significant clinical challenge. Medical treatment is considered the first-line treatment for inflammatory strictures, and anti-TNF agents appear to provide the most considerable benefit among the available medical treatments. However, medical therapy is ineffective on strictures with a mainly fibrotic component, and a high proportion of patients under anti-TNF will require surgery. In fibrotic strictures or cases refractory to medical treatment, an endoscopic or surgical approach should be considered depending on the location, length, and severity of the stricture. Both endoscopic balloon dilatation and endoscopic stricturoplasty are minimally invasive and safe, associated with a small risk of complications. On the other hand, the surgical approach is indicated in patients not suitable for endoscopic therapy. This review aimed to present and analyze the currently available medical, endoscopic, and surgical management of stricturing Crohn’s disease.


  • Association of clinical and inflammatory markers with small bowel capsule endoscopy findings in Crohn’s disease

    by Ioannis V. Mitselos, Konstantinos H. Katsanos, Athina Tatsioni, Alexandros Skamnelos, Rami Eliakim, Epameinondas V. Tsianos, Dimitrios K. Christodoulou

    Background: Mucosal healing is an established treatment endpoint in Crohn’s disease (CD). Still, clinical indices and inflammatory markers are used widely in CD surveillance. Aim: The aim of this study was to investigate the diagnostic performance as well as the relationship of C-reactive protein (CRP) and Crohn’s Disease Activity Index (CDAI) with small bowel capsule endoscopy’s (SBCE) inflammation scoring index, the Lewis Score (LS). Patients and methods: CDAI, CRP, and SBCE findings of 30 CD patients with isolated small bowel disease were retrieved from our academic institution patient records and were analyzed statistically. Results: SBCE showed significant mucosal inflammation [mean (SD) LS: 1599 (1380)], in nine (60.0%) of 15 patients who were in both clinical and biochemical remission. CDAI and CRP showed a weak and moderate correlation with LS (r=0.317, P=0.088 and r=0.516, P=0.004, respectively). The diagnostic performance of CDAI and CRP in predicting mucosal inflammation was as follows: sensitivity 23.8 and 52.4%; specificity 100 and 66.7%; positive predictive value 100 and 78.6%; and negative predictive value 36.0 and 37.5%. The area under the curve toward endoscopic activity prediction was 0.70 and 0.69, respectively. Conclusion: Both CDAI and CRP underestimated endoscopic activity as expressed by the LS in a significant proportion of patients with quiescent disease.


  • What defines quality in small bowel capsule endoscopy

    by Ioannis V. Mitselos, Dimitrios K. Christodoulou

    Small bowel capsule endoscopy is considered a first-line diagnostic tool for the investigation of small bowel diseases. Gastroenterological and endoscopic societies have proposed and established measures known as quality indicators, quality measures or performance measures for the majority of endoscopic procedures, in order to ensure competence, healthcare quality and define areas requiring improvement. However, there is a paucity of publications describing small bowel capsule endoscopy quality indicators. Hereby, we attempt to identify and describe a number of pre-procedure, intra-procedure and post-procedure quality indicators, regarding process measures in small bowel capsule endoscopy, after a comprehensive review of the literature.


  • Clinical Use of Patency Capsule: A Comprehensive Review of the Literature

    by Ioannis V Mitselos, Konstantinos Η Katsanos, Epameinondas V Tsianos, Rami Eliakim, Dimitrios Κ Christodoulou

    The patency capsule is a radiopaque, dissolvable diagnostic tool, similar in shape and size to small bowel capsule endoscopes. It was developed to offer a simple, safe, efficient, and accurate evaluation of small bowel functional patency. Although unable to provide direct visual information regarding the presence and location of strictures, masses, or luminal narrowing of the small bowel, a successful patency test minimizes the risk of retention and allows the safe administration of a capsule endoscope. However, its use entails a low risk of potentially harmful adverse events, which in their majority are indolent and resolve spontaneously. Abdominal pain and symptomatic retention are accountable for the majority of reported adverse events, whereas a limited number of reports describe life-threatening complications, namely intestinal obstruction, perforation, and intestinal ischemia. Computed tomography is the modality of choice for the identification of the exact position of an impacted patency capsule, whilst the use of plain abdominal radiographs should be avoided for the evaluation of the patency capsule position, as they provide false information. Hereby, we present a comprehensive review of the available literature regarding the characteristics, indications, clinical use, effectiveness, and adverse events of the patency capsule.


  • The role of small bowel capsule endoscopy and ileocolonoscopy in patients with nonspecific but suggestive symptoms of Crohn’s disease

    by Ioannis V. Mitselos, Dimitrios K. Christodoulou, Konstantinos H. Katsanos, Athina Tatsioni, Aleksandra Rapti, Rami Eliakim, Epameinondas V. Tsianos

    IC should be the initial diagnostic test in patients with nonspecific, but suggestive symptoms of CD. SBCE offers additional information on small bowel mucosa and disease extent.


  • Open Access

    Ascites in the Puerperium in the Context of a Woman with Turner Syndrome Who Conceived through Assisted Reproductive Technology

    by Nikolaos Tsagkas, George Valasoulis, Konstantinos Zikopoulos, Calliope Zerzi, Ioannis Mitselos, Ioannis Koutoulakis, Nikolaos Tzampouras, Theodor Stefos

    The case is about a young female who delivered twins by caesarean section (CS). On the 4th postoperative day, she presented with ascites which was resistant to empirical antibiotic and diuretic treatment. The woman was affected by Turner syndrome (TS); she had a medical background of chronic use of hormonal medication since puberty and conceived through ART- (assisted reproduction techniques-) IVF-oocyte donation. It is important to exhibit high suspicion for clot formation in the hepatic vasculature during the puerperium, especially in the case of history of chronic hormone treatment. Ascites albumin gradient and Doppler values lead to the diagnosis of thrombosis and the administration of high doses of anticoagulants is considered to be fundamental.


  • Open Access

    Role of wireless capsule endoscopy in the follow-up of inflammatory bowel disease

    by Ioannis V Mitselos, Dimitrios K Christodoulou, Konstantinos H Katsanos, Epameinondas V Tsianos

    Role of wireless capsule endoscopy in the follow-up of inflammatory bowel disease